GSK vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GSK presents a compelling value proposition characterized by a Piotroski F-Score of 4/9 (Stable) and a significant disconnect between its current price ($54.22) and its growth-based intrinsic value ($110.92). While short-term liquidity is a concern with a Current Ratio of 0.82, the company's operational efficiency is exceptional, evidenced by an ROE of 43.31% and a very low PEG ratio of 0.50. A long-term track record of earnings beats suggests strong management execution. However, the bearish technical trend (0/100) indicates that the market has not yet priced in these fundamental strengths.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GSK vs MRK: Head-to-Head Comparison
This page compares GSK plc (GSK) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.